CLINICAL TRIALS PROFILE FOR ANZEMET
✉ Email this page to a colleague
All Clinical Trials for ANZEMET
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00360828 ↗ | Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas | Terminated | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | 2006-02-01 | Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine. At each cycle, patient exams and interviews as well as lab results were to help the research team to determine the symptomatic side effects of the treatment. Recorded past toxicities were to be compared with current side effects. |
| NCT00820326 ↗ | Efficacy of Dolasetron in Patients With Fibromyalgia | Completed | University Hospital, Limoges | Phase 3 | 2004-03-01 | This study offers a new treatment, dolasetron or ANZEMET ®, which will be administered by intravenous way once a day during a 4 days Hospitalization. This study is double blind (neither you nor the physician will know if you are receiving active study drug or placebo). Randomisation at the beginning of the study will decide whether you receive active treatment or its placebo. This treatment will be renewed after one month, after 2 months and after 3 months. If the study staff determines that you are eligible and you decide to participate, there will be approximately 6 study visits in about 9 months. During these visits, you will undergo routine health exams and complete different kinds of questionnaires. Following this first period of 3 months, you agree to come back for consultation at month 4, month 6 and month 12 for monitoring and evaluating the effects of treatment. |
| NCT01360593 ↗ | Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma | Completed | David A. Clump, MD, PhD | Phase 2 | 2011-07-25 | The current study seeks to further investigate the impact of up-front systemic therapy in combination with fractionated SBRT for potentially resectable, locally-advanced pancreatic adenocarcinoma. |
| NCT01360593 ↗ | Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma | Completed | University of Pittsburgh | Phase 2 | 2011-07-25 | The current study seeks to further investigate the impact of up-front systemic therapy in combination with fractionated SBRT for potentially resectable, locally-advanced pancreatic adenocarcinoma. |
| NCT02550119 ↗ | Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy | Terminated | National Cancer Institute (NCI) | N/A | 2006-04-19 | This randomized pilot clinical trial dolasetron mesylate and dexamethasone with or without aprepitant in preventing nausea and vomiting in patients undergoing oxaliplatin-containing chemotherapy for gastrointestinal malignancy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. It is not yet known whether giving aprepitant together with dolasetron mesylate and dexamethasone is more effective than dolasetron mesylate and dexamethasone alone in preventing nausea and vomiting. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ANZEMET
Condition Name
Clinical Trial Locations for ANZEMET
Trials by Country
Clinical Trial Progress for ANZEMET
Clinical Trial Phase
Clinical Trial Sponsors for ANZEMET
Sponsor Name
